Table 1 Patient characteristics
|  | All patients (n = 196) | |
|---|---|---|
# | % | |
Age at diagnosis, years | ||
 <60 | 120 | 61.2 |
 >60 | 76 | 38.8 |
Primary site | ||
 Oropharynx | 145 | 74.0 |
 Larynx | 51 | 26.0 |
Gender | ||
 Male | 171 | 87.2 |
 Female | 25 | 12.8 |
Race | ||
 White | 171 | 25 |
 Other | 87.2 | 12.8 |
Tobacco use (pack years) | ||
 <10 | 106 | 54.1 |
 ≥10 | 90 | 45.9 |
Karnofsky performance score | ||
 >80 | 140 | 71.4 |
 ≤80 | 56 | 28.6 |
T-stage | ||
 T1 | 102 | 52 |
 T2 | 56 | 28.6 |
 T3 | 30 | 15.3 |
 T4 | 8 | 4.1 |
N-stage | ||
 N0–1 | 61 | 31.1 |
 N2a–2b | 91 | 46.4 |
 N2c–3 | 44 | 22.4 |
Post-operative radiation | ||
 Yes | 48 | 24.5 |
 No | 148 | 75.5 |
HPV | ||
 Negative | 51 | 26 |
 Positive | 99 | 50.5 |
 Unknown | 46 | 23.5 |
Chemotherapy | ||
 None | 14 | 7.1 |
 Cisplatin, weekly | 38 | 19.4 |
 Cisplatin, q3 weeks | 39 | 19.9 |
 Carboplatin + paclitaxel | 38 | 19.4 |
 Cetuximab | 57 | 29.1 |
 Cisplatin + cetuximab | 10 | 5.1 |
Overall survival, years | ||
 Median | 2.7 | |
 Mean | 3.39 | |
 95% CI | 3.04–3.75 | |